(phenyl)-[α-(allylamino)benzyl]-ketone | 22312-19-2

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: (phenyl)-[α-(allylamino)benzyl]-ketone
• 英文别名: α-Allylamino-α'-oxobibenzyl；α-Allylamino-desoxybenzoin；1,2-Diphenyl-2-(prop-2-enylamino)ethanone
• CAS: 22312-19-2
• 化学式: C₁₇H₁₇NO
• 分子量: 251.328
• InChiKey: GEUFTFWKQNWJDZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  19
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (phenyl)-[α-(allylamino)benzyl]-ketone 、 丙二腈 以 甲苯 为溶剂， 反应 0.75h， 以13.7 g的产率得到1-allyl-2-amino-4,5-diphenyl-1H-pyrrole-3-carbonitrile
  参考文献：
  名称：

  Synthesis and cytotoxic activity of 5,6-heteroaromatically annulated pyridine-2,4-diamines

  摘要：

  A series of 5,6-heteroaromatically annulated pyridine-2,4-diamines have been synthesized and their in vitro cytotoxic activities evaluated against six human cancer cell lines. Benzo[g] annulated pyrido[2,3-b]indolediamines 7a-b and 8 showed relatively high cytotoxic activity as well as most of the diamines with pyrrolo[2,3-b] pyridine 17, thieno[2,3-b] pyridine and furo[2,3-b] pyridine 26-28, 1,8-naphthyridine 32 and 34 and benzo[h] quinoline 37 skeletons. Surprisingly, pyrido[2,3-b] indolediamines 13 and 14 without benzo[g] annulation were inactive. None of the new compounds were as potent as ellipticine, the reference compound. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2009.05.016
• 作为产物：
  描述：

  安息香精油 、 丙烯胺 在 对甲苯磺酸 作用下， 以 甲苯 为溶剂， 反应 1.0h， 生成 (phenyl)-[α-(allylamino)benzyl]-ketone
  参考文献：
  名称：

  Synthesis and cytotoxic activity of 5,6-heteroaromatically annulated pyridine-2,4-diamines

  摘要：

  A series of 5,6-heteroaromatically annulated pyridine-2,4-diamines have been synthesized and their in vitro cytotoxic activities evaluated against six human cancer cell lines. Benzo[g] annulated pyrido[2,3-b]indolediamines 7a-b and 8 showed relatively high cytotoxic activity as well as most of the diamines with pyrrolo[2,3-b] pyridine 17, thieno[2,3-b] pyridine and furo[2,3-b] pyridine 26-28, 1,8-naphthyridine 32 and 34 and benzo[h] quinoline 37 skeletons. Surprisingly, pyrido[2,3-b] indolediamines 13 and 14 without benzo[g] annulation were inactive. None of the new compounds were as potent as ellipticine, the reference compound. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2009.05.016

文献信息

• [EN] CHEMICAL COMPOUNDS<br/>[FR] COMPOSES CHIMIQUES
  申请人：ASTRAZENECA AB

  公开号：WO2004011410A1

  公开（公告）日：2004-02-05

  Compounds of formula (I):wherein variable groups are as defined within; for use in the inhibition of 11βHSD1 are described.

  式(I)的化合物：其中变量基团如定义内；用于抑制11βHSD1。
• [EN] 7-ARYL-3,9-DIAZABICYCLO(3.3.1)NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES<br/>[FR] DERIVES DE 7-ARYL-3,9-DIAZABICYCLO(3.3.1)NON-6-ENE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE RENINE DANS LE TRAITEMENT DE L'HYPERTENSION, DE MALADIES CARDIOVASCULAIRES OU RENALES
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2003093267A1

  公开（公告）日：2003-11-13

  The invention relates to novel 3,9-diazabicyclo[3.3.1]nonene derivatives of formula (I) and related compounds and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as inhibitors or renin.

  该发明涉及新型3,9-二氮杂双环[3.3.1]壬烯衍生物（I）及相关化合物，以及它们作为药物组合物中活性成分的用途。该发明还涉及相关方面，包括制备这些化合物的过程、含有这些化合物中的一个或多个的药物组合物，尤其是它们作为肾素抑制剂的用途。
• Ketones
  申请人：Barton John Peter

  公开号：US20050272036A1

  公开（公告）日：2005-12-08

  Compounds of formula (I): wherein variable groups are as defined within; for use in the inhibition of 11βHSD1 are described.

  描述了式(I)的化合物：其中变量基团如定义的那样；用于抑制11βHSD1。
• 7-ARYL-3,9-DIAZABICYCLO[3.3.1]NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES
  申请人：Actelion Pharmaceuticals Ltd.

  公开号：EP1501830A1

  公开（公告）日：2005-02-02
• KETONES
  申请人：AstraZeneca AB

  公开号：EP1549600A1

  公开（公告）日：2005-07-06